Navigation Links
Fidia Farmaceutici S.p.A. to Distribute and Promote HYALGAN® (sodium hyaluronate) for Treatment of Osteoarthritis
Date:9/26/2011

PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Fidia Farmaceutici S.p.A. ("Fidia") announced today that it has assumed responsibility for distributing and promoting the osteoarthritis (OA) treatment, Hyalgan (sodium hyaluronate), in the United States through its wholly-owned subsidiary, Fidia Pharma USA Inc. ("Fidia USA"). Fidia USA has engaged Interpace BioPharma, LLC. ("Interpace") to provide commercialization services to support Hyalgan.

Hyalgan was introduced in Italy in 1987. In 1997, Hyalgan became the first viscosupplementation product approved for marketing by the U.S. Food and Drug Administration.  More than 38 million doses of Hyalgan have been administered worldwide since its introduction.(1) Hyalgan is indicated to relieve pain associated with osteoarthritis (OA) of the knee when simple analgesics like acetaminophen have failed.

"We are pleased to continue providing a treatment that has helped millions of patients worldwide who have suffered the debilitating effects of osteoarthritis," said Antonio Germani, CEO of Fidia Farmaceutici S.p.A.  "Hyalgan has demonstrated its safety and efficacy in more than 90 clinical trials involving more than 13,000 patients.  Our commitment is to provide our customers and patients the quality service they deserve, including reimbursement and patient assistance as well as patient education materials. Our goal is to see to it that Hyalgan remains a sustainable treatment of choice for patients with knee pain associated with OA," said Germani.

About Osteoarthritis (OA)

According to the Arthritis Foundation, 27 million Americans suffer from OA, which is common in all races and backgrounds.  The condition usually appears after the age of 45 years. Men under age 55 years are more likely to have osteoarthritis than women in the same age range.  After 55 years, women are more commonly affected.  OA is a chronic condition characterized by the breakdown of the joint cartilage and synovial fluid, which acts as both as a lubricant and shock absorber for the knee joint.  The breakdown of the cartilage and synovial fluid causes the bones to rub against each other, causing stiffness, pain and loss of movement in the joint. While there is no cure for OA, current disease management focuses on controlling joint pain and stiffness.  

About Hyalgan

Hyalgan is based on natural hyaluronic acid which is structurally and chemically similar to hyaluronic acid that is present in the knees of healthy individuals.  Hyaluronic acid is a vital natural component of the cartilage and synovial fluid of the knee joint.

"For many years, Hyalgan has served as an important therapeutic option for sufferers of osteoarthritis," said Dr. Frank Kane of Fidia Pharma Inc.  "Its long-established safety and efficacy record has demonstrated its usefulness in relieving the pain of osteoarthritis in patients who do not get relief from simple analgesics, such as acetaminophen, or are unable to tolerate the side effects of non-steroidal anti-inflammatory agents," continued Kane.

The recommended treatment cycle for Hyalgan is five intra-articular injections given once a week for five weeks, although many patients receive significant pain relief after a three-injection regimen consisting of one injection per week for three weeks.  Hyalgan will relieve pain in a many patients for up to six months.  Hyalgan is only approved to relieve knee pain. The FDA has not evaluated Hylagan's safety and efficacy in other joints.  Full prescribing information and important safety information for Hyalgan can be found at http://www.hyalgan.com.

About Fidia Farmaceutici S.p.A

Headquartered in Abano Terme, Northeast Italy, Fidia Farmaceutici S.p.A., has over 50 years of successful R&D and industry experience with biologically active molecules.  As a model for international success, Fidia has focused its core business activities on hyaluronic acid and glycosaminoglycan derivates, developing and providing a wide range of products for various specialties. Fidia holds more than 960 patents on hyaluronic acid and its applications and its products are currently available in over 70 countries worldwide.  Fidia's most important proprietary platform technology at a worldwide level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering therapeutic categories such a Joint Care, Advanced Wound Care, and Aesthetic Dermatology.

Helping people stay healthy is Fidia's corporate commitment.  For more information, visit www.fidiapharma.com.

About Interpace BioPharma, LLC.

Located in Parsippany, NJ, Interpace is a wholly owned subsidiary of PDI, Inc., a leading company that provides a wide range of commercialization services to the life science industry. Interpace provides marketing, sales, and product distribution support to manufacturers of pharmaceutical and biological drugs, medical devices and clinical diagnostics.  

(1) Data on File, Fidia Farmaceutici S.p.A.


'/>"/>
SOURCE Fidia Farmaceutici S.p.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A.
2. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
3. VWR International, LLC Acquires INTERNATIONAL P.B.I. S.p.A.
4. OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010
5. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
6. Osteotechs MagniFuse(TM) Distributed to 68 U.S. Hospitals as Product Revenue Surpasses $1 Million
7. Par Obtains Exclusive Rights to Market and Distribute Generic Zetia(R) in the U.S.
8. Patient Advocacy Group Distributes Wallet Cards to Help Protect Patients from Medication Switching
9. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
10. Draeger Announces Partnership With L. N. Curtis & sons to Distribute Emergency Responder Equipment
11. As Cholera Outbreak Spreads, World Vision Deploys Teams to Distribute Emergency Health Supplies, Focus on Preventative Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/22/2017)... ... 2017 , ... Branches, Inc. has been partnering with The Miami Foundation for ... its programs focused on providing opportunity to low-income families and breaking the cycle of ... of $15,000 to support its , Climb to College & Career initiative which focuses ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many physicians are unfamiliar ... integrate basic science with clinical practice. Now, however, a timely review has been published ... insight into the etiology of NeuP and educating preclinical scientists on its diagnosis and ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., a leading ... eBook titled “ 5 Questions to Ask Before Entering the Maze of Genetic ... Test Evaluation (GTE) team, the book explores the various types of the more ...
Breaking Medicine News(10 mins):